TEVA PHARMACEUTICAL INDUSTRIES LIMITED — Net Income by Fiscal Year
19 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/c2a4a084-a235-4d9a-a95a-7cd46ef5ddc4/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $1.4B | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-034532 |
| FY 2024 | $-1.6B | 2024-01-01 – 2024-12-31 | evidence 0001193125-25-020826 |
| FY 2023 | $-559.0M | 2023-01-01 – 2023-12-31 | evidence 0001193125-24-031005 |
| FY 2022 | $-2.4B | 2022-01-01 – 2022-12-31 | evidence 0001193125-24-031005 |
| FY 2021 | $417.0M | 2021-01-01 – 2021-12-31 | evidence 0001193125-22-032667 |
| FY 2020 | $-4.0B | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-036239 |
| FY 2019 | $-999.0M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-044221 |
| FY 2018 | $-2.1B | 2018-01-01 – 2018-12-31 | evidence 0001193125-19-043564 |
| FY 2017 | $-16.3B | 2017-01-01 – 2017-12-31 | evidence 0001193125-18-039076 |
| FY 2016 | $329.0M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-045463 |
| FY 2015 | $1.6B | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-459785 |
| FY 2014 | $3.1B | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-039151 |
| FY 2013 | $1.3B | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-041871 |
| FY 2012 | $2.0B | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-050510 |
| FY 2011 | $2.8B | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-067417 |
| FY 2010 | $3.3B | 2010-01-01 – 2010-12-31 | evidence 0001193125-11-036753 |
| FY 2009 | $2.0B | 2009-01-01 – 2009-12-31 | evidence 0001193125-10-036435 |
| FY 2008 | $609.0M | 2008-01-01 – 2008-12-31 | evidence 0001193125-10-036435 |
| FY 2007 | $1.9B | 2007-01-01 – 2007-12-31 | evidence 0001193125-10-036435 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
TEVA PHARMACEUTICAL INDUSTRIES LIMITED — all facts · Revenue · Operating Income